513 related articles for article (PubMed ID: 16372516)
41. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Bertolini S; Bon GB; Campbell LM; Farnier M; Langan J; Mahla G; Pauciullo P; Sirtori C; Egros F; Fayyad R; Nawrocki JW
Atherosclerosis; 1997 Apr; 130(1-2):191-7. PubMed ID: 9126664
[TBL] [Abstract][Full Text] [Related]
42. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
43. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis.
Geiss HC; Parhofer KG; Schwandt P
J Intern Med; 1999 Jan; 245(1):47-55. PubMed ID: 10095816
[TBL] [Abstract][Full Text] [Related]
44. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Endo K; Miyashita Y; Saiki A; Oyama T; Koide N; Ozaki H; Otsuka M; Ito Y; Shirai K
J Atheroscler Thromb; 2004; 11(6):341-7. PubMed ID: 15644588
[TBL] [Abstract][Full Text] [Related]
45. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
46. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
47. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
48. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
Sirtori CR; Calabresi L; Pisciotta L; Cattin L; Pauciullo P; Montagnani M; Manzato E; Bittolo Bon G; Fellin R
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):47-55. PubMed ID: 15871851
[TBL] [Abstract][Full Text] [Related]
49. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN
Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573
[TBL] [Abstract][Full Text] [Related]
50. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
51. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
Wanner C; Krane V
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S72-5. PubMed ID: 12612957
[TBL] [Abstract][Full Text] [Related]
52. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
53. [Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Scheen AJ; Kulbertus H
Rev Med Liege; 2004 Mar; 59(3):167-73. PubMed ID: 15139406
[TBL] [Abstract][Full Text] [Related]
54. [The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Broncel M; Koter-Michalak M; Chojnowska-Jezierska J
Przegl Lek; 2006; 63(9):738-42. PubMed ID: 17479860
[TBL] [Abstract][Full Text] [Related]
55. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Cho Y; Choe E; Lee YH; Seo JW; Choi Y; Yun Y; Wang HJ; Ahn CW; Cha BS; Lee HC; Kang ES
Metabolism; 2015 Apr; 64(4):482-8. PubMed ID: 25312577
[TBL] [Abstract][Full Text] [Related]
56. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
[TBL] [Abstract][Full Text] [Related]
57. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
Ansell BJ; Watson KE; Weiss RE; Fonarow GC
Heart Dis; 2003; 5(1):2-7. PubMed ID: 12549983
[TBL] [Abstract][Full Text] [Related]
58. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
Oka H; Ikeda S; Koga S; Miyahara Y; Kohno S
Heart Vessels; 2008 Jul; 23(4):249-56. PubMed ID: 18649055
[TBL] [Abstract][Full Text] [Related]
59. Hemostatic effects of atorvastatin versus simvastatin.
Kadikoylu G; Yukselen V; Yavasoglu I; Bolaman Z
Ann Pharmacother; 2003 Apr; 37(4):478-84. PubMed ID: 12659599
[TBL] [Abstract][Full Text] [Related]
60. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]